^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Excerpt:
...NRAS, HRAS, BRAF, MEK, and ERK mutations....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Go to data
Title:

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Excerpt:
...- Group 1: Patients with BRAF mutated cancer, except those with colorectal or non-small cell lung cancers...
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Title:

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Excerpt:
Ulixertinib has an acceptable safety profile with favorable pharmacokinetics and has shown early evidence of clinical activity in NRAS- and BRAF V600- and non-V600-mutant solid-tumor malignancies….In 19 such patients with BRAF-mutant melanoma previously treated with a BRAF and/or MEK inhibitor, 3 (15%) achieved a PR, 6 had stable disease, and 10 had progressive disease as a best response.
DOI:
10.1158/2159-8290.CD-17-1119
Trial ID: